CRISPR gene-editing stocks are being hit hard by a broader biotech sell-off on Tuesday. Shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 9.1% as of 12:05 p.m. EST. Editas Medicine (NASDAQ: EDIT) stock had declined 13.7%, while Intellia Therapeutics (NASDAQ: NTLA) shares had slumped 11.4%.
There wasn’t a clear reason behind today’s rout of biotech stocks. The biggest negative story in the biopharmaceutical industry centered on Arcturus Therapeutics‘ disappointing early-stage results for its single-dose COVID-19 vaccine candidate.